1. Navaneethan SD, Sakhuja A, Arrigain S, Sharp J, Schold JD, Nally JV Jr (2014) Practice patterns of phosphate binder use and their associations with mortality in chronic kidney disease. Clin Nephrol 82:16–25
2. Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, Li X, Chen J, Liu B, La Y, Hou F, Ni Z, Fu J, Xing C, Yu X, Huang C, Zuo L, Wang L, Hunter J, Dillon M, Plone M, Neylan J (2014) Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study. Nephrol Dial Transplant 29:152–160
3. Wang C, Liu X, Zhou Y, Li S, Chen Y, Wang Y, Lou T (2015) New conclusions regarding comparison of sevelamer and calcium-based phosphate binders in coronary-artery calcification for dialysis patients: a meta-analysis of randomized controlled trials. PLoS One 10:e0133938
4. Madan P, Bhayana S, Chandra P, Hughes JI (2008) Lower gastrointestinal bleeding: association with sevelamer use. World J Gastroenterol 14:2615–2616
5. Swanson BJ, Limketkai BN, Liu TC, Montgomery E, Nazari K, Park JY, Santangelo WC, Torbenson MS, Voltaggio L, Yearsley MM, Arnold CA (2013) Sevelamer crystals in the gastrointestinal tract (GIT): a new entity associated with mucosal injury. Am J Surg Pathol 37:1686–1693